L-146-2023

Agreement ID
L-146-2023
Lead IC
NCI
Exclusivity
Exclusive
External Party
BrickBio, Inc.
Fiscal Year
2024
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4393     Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer
TAB-4275     Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276